This bill amends Section 5030.1 of Title 63 of the Oklahoma Statutes, which pertains to the Medicaid Drug Utilization Review Board. Key modifications include changes to the appointment procedures for board members, specifically reducing the number of physician candidates submitted by the Oklahoma State Medical Association from six to three. Additionally, the bill updates the terminology used for the Oklahoma Pharmacists Association and clarifies that the member representing the pharmaceutical industry must be a resident of the state. The bill also stipulates that the board will elect a vice chair instead of a vice-chair, and it emphasizes the need for geographic balance in member representation.

The bill establishes that the Medicaid Drug Utilization Review Board will consist of ten members, including four physicians, four pharmacists, one lay community representative, and one pharmaceutical industry representative. Members will serve staggered terms of three years, with some initially appointed for two-year terms to ensure continuity. The board is tasked with developing and assessing drug utilization programs and must comply with the Oklahoma Open Meeting Act and the Administrative Procedures Act. The act is set to take effect on November 1, 2025.